time during the first month following amputation and resolves in many patients after 2-3 years without treatment, except in cases in which phantom pain develops. The incidence of phantom pain is variable but increases with more proximal amputations. The origin and pathophysiological mechanisms of phantom pain are not clearly defined. However, both peripheral and central neural mechanisms have been described, along with superimposed psychological mechanisms. The management of phantom limb pain has little evidence base in the scientific literature; while numerous treatments have been described, there is little clinical evidence supporting any particular therapy.
Thalamic deep brain stimulation for neuropathic pain after amputation or brachial plexus avulsion Brachial plexus avulsion (BPA) commonly results in early deafferentation pain, with 25% of sufferers going on to experience severe neuropathic pain several years later that is usually refractory to pharmacotherapy. 45 Brachial plexus avulsion pains have been dichotomized into either continuous, often burning or throbbing pain and likely involving thalamic neuroplasticity, or shooting paroxysms associated with dorsal horn hyperactivity. 48, 49 Both phantom limb pain after amputation and deafferentation pain after BPA fulfill a recently revised definition of neuropathic pain as pain caused by a lesion or disease of the somatosensory system. 27 Neuropathic pain symptom severity and duration are often greater than other forms of chronic pain, leading patients and clinicians to consider neurosurgery. 59 Deep brain stimulation (DBS) is an invasive neurosurgical intervention established in movement disorders and also used to treat "off-label" clinical indications of epilepsy, Tourette syndrome, obsessive-compulsive disorders, depression, and cluster headache. 51 Deep brain stimulation has been performed for more than half a century for chronic pain amelioration, 21 its use preceding gatecontrol theory by a decade. 43 After rodent self-stimulation experiments and reported analgesia in patients receiving septal DBS, 47 cancer pain was being relieved by intermittent stimulation by the 1960s. 16, 22 Evidence supporting the ventroposterolateral nucleus of the sensory thalamus (ventroposterolateral) as a target for limb pain came from ablative surgery. 41 The ventroposterolateral nucleus of the sensory thalamus has been targeted successfully for 4 decades, 25 as has periaqueductal and periventricular gray matter. 57 Two multicenter trials of DBS for pain were conducted to seek US FDA approval. 7 Neither trial satisfied efficacy criteria of at least half of the patients reporting at least 50% pain relief 1 year after surgery. United States FDA approval was therefore not sought. Deep brain stimulation for pain was decreed "off label," precluding medical insurance reimbursement. Consequently, few surgeons currently report DBS for pain outside of Europe, where it has approval by the European Federation of Neurological Societies (EFNS) and the United Kingdom National Institute for Health and Clinical Excellence (NICE). 9, 46 Nevertheless, a recent growing interest in its use for chronic pain refractory to medical treatment has paralleled advances in DBS technology, neuroimaging, and the publication of more rigorous case series regarding its long-term efficacy. Successful results have been shown for multiple origins of pain, in particular for poststroke pain, face pain, amputation, and BPA. 5 In this paper we describe a prospectively studied, open-label, consecutive case series of patients receiving ventroposterolateral DBS for chronic neuropathic pain after amputation or BPA. These patients were treated at a single Portuguese center that was establishing DBS for pain service after a decade's experience of using DBS for movement disorders in more than 200 patients. Improvements in patient-reported outcome measures of pain and quality of life were analyzed, and challenges to DBS for pain are discussed.
Methods

Study Population
Patients were referred by clinicians nationally (in Portugal) to a single-center multidisciplinary team consisting of pain specialists, neurologists, neuropsychologists, and neurosurgeons at Hospital de São João in Porto, Portugal. Neuropsychological evaluation excluded psychiatric disorders and ensured minimal cognitive impairment. Neuropathic medications and other surgical treatments may have been attempted with limited success. Selection criteria included neuropathic pain refractory to medicines for at least 2 years, together with absence of surgical contraindications such as coagulopathy or ventriculomegaly. Informed consent was obtained and the study received local ethical board approval. Patients were counseled for the possibility that they may derive no benefit from ventroposterolateral DBS or not tolerate it well, necessitating its removal.
Deep Brain Stimulation Procedure
For surgery, a Leksell stereotactic frame (Elekta Instruments) was applied to the patient's shaved head under local anesthesia. A stereotactic head CT scan with a 2-mm slice thickness was performed, with preoperative T1-and T2-weighted MR images of 2-mm slice thickness from a 1.5-T scanner volumetrically fused to the scan using FrameLink stereotactic calculation software (Medtronic). The Leksell stereotactic arc was then fixed to its frame on the awake, semisitting patient. Intravenous vancomycin and cefotaxime antibiotic prophylaxis and dexamethasone were routinely administered before surgery commenced. After bur hole exposure, a Leksell radiofrequency electrode impedance check was performed to 10 mm above target, then DBS electrode insertion to target, and intraoperative C-arm radiographic target confirmation.
A guiding principle in awake electrode targeting is the established somatotopic organization of the somaesthetic thalamic nuclei. Human microelectrode studies have revealed a mediolateral somatotopy in the contralateral ventral posterior thalamus, with the head of the homunculus medial and the feet lateral. 34 The contralateral ventroposterolateral nucleus of the sensory thalamus was targeted for limb pain and found in the plane 10-13 mm posterior to the midcommissural point, and from 5 mm below to 2 mm above it. The arm area of the ventroposterolateral nucleus of the sensory thalamus was 2-3 mm medial, and leg area 1-2 mm medial, to the internal capsule. Thus, targeting was generally 12-14 mm lateral and 0-2 mm anterior to the posterior commissure. A transfrontal extraventricular trajectory from an entry point on or near the coronal suture to the ipsilateral ventroposterolateral nucleus of the sensory thalamus was planned, avoiding blood vessels and sulci.
Targets were implanted with Medtronic Model 3387 quadripolar electrodes with 0.5-mm contacts spaced 1.5 mm apart. Final electrode position was determined by intraoperative clinical assessment that relied upon subjective reporting by the awake patient rather than microelec-trode recording. Tactile stimulation of the painful body part was performed intraoperatively to augment pain and assess response if necessary. At either target during surgery, DBS at lower frequencies (≤ 50 Hz) was analgesic and higher frequencies (> 70 Hz) hyperalgesic. Bipolar stimulation of 5-50 Hz was performed initially, with a pulse width of 200-450 μs and amplitude of 0.5-5 V. Stimulation of the ventroposterolateral nucleus of the sensory thalamus aimed to supplant painful sensation by pleasant paresthesias. Adjustment was primarily somatotopic, with the assessor alert to pyramidal signs suggesting capsular involvement. The electrode was rarely moved from its planned target, but occasionally moved 2 mm at a time lateral, medial, proximal, or distal during awake testing to optimize somatotopic coverage. Once satisfactory targeting had been achieved by microdrive adjustment, the patient's electrode was secured in place with a Stimloc skull fixation device (Medtronic). Electrode leads were externalized parietally via temporary extensions, and electrode position was confirmed by postoperative stereotactic CT, again fused to preoperative MRI. Typical surgery duration was 2-3 hours, including stereotactic planning.
Bedside DBS programming was undertaken during the postoperative period both morning and afternoon, in sessions lasting approximately 30 minutes per patient. Different frequencies from 5 to 50 Hz were used alongside varied bipolar stimulation over different contacts at increasing pulse widths and amplitudes to optimize analgesia without unpleasant sensations in the painful body part. Typically, pleasant paresthesia was elicited and occasionally analgesia without paresthesia, mirroring intraoperative results (Video 1). After 48 hours of postoperative clinical assessment, a decision was made whether to permanently implant the electrodes under general anesthesia. The electrodes were connected to a pulse generator (Medtronic Kinetra or Activa PC) implanted in the chest via new extension leads. During postoperative assessment, each patient recorded visual analog scale (VAS) scores at least twice daily at set times while blinded to DBS settings. Targets were tested using analgesic stimulation parameters to determine which electrode contacts conferred maximum analgesia. Visual analog scale scores were averaged for the trial period and compared with preoperative scores to assess for improvement. The decision to proceed to implantation of the pulse generator was made for each individual patient, guided by the multidisciplinary team.
Patients ideally left the hospital a day after implantation of the pulse generator, with progress followed up by clinic appointments at 1, 3, and 6 months, and then yearly thereafter. Continuous rather than on-demand stimulation was encouraged, but in addition to the ability to switch the DBS on and off at will, patients were usually given control over its voltage only, which was typically limited by the clinician to a maximum amplitude of 4 V.
Outcome Assessment
Quantitative assessment of pain and health-related quality of life were performed 1 month before surgery and postoperatively at 1, 3, and 6 months, and then annually by independent, blinded assessors trained in pain medicine but not involved in caring for the patient and unaware of the details of the neurosurgical treatment given. The VAS to rate pain intensity, the University of Washington Neuropathic Pain Score (UWNPS), and Brief Pain Inventory (BPI) were used. 6, 14 Patients recorded VAS scores twice daily in a pain diary over 14 days. The 28 VAS scores were reviewed to ensure consistency, and the mean was then calculated.
Patients also completed a 36-Item Short-Form Health Survey (SF-36) on quality of life along with the pain questionnaires. The SF-36 responses were regrouped into 8 domains of physical functioning: role (physical), bodily pain, general health, vitality, social functioning, role (emotional), and mental health. Results were scored by online tools (http://www.sf-36.org/demos/sf-36.html). Norm-based scores allowed comparison between studies.
Statistical Analysis
As pain assessments were made as repeated measures throughout the follow-up, preoperative and postoperative scores were compared for each group of patients using a general linear mixed model, with a p value < 0.05 considered statistically significant and p < 0.01 considered highly significant. Table 1 lists the demographic characteristics of 12 consecutive patients treated over 3 years with DBS surgeries between January 2009 and May 2011, including pain origin, relevant preoperative medications, stimulation parameters, and baseline preoperative and long-term (12-month) postoperative VAS scores. Ten patients (83%) were male, 2 female (17%), and the mean age of the study population was 53.6 ± 9.8 years old. All patients suffered traumatic injuries, and only 1 was not due to a motor vehicle accident. All amputees experienced phantom pain and all BPAs had preganglionic involvement. No patients with BPA underwent amputations and no amputees had BPA. The mean duration of symptoms before surgery was 20 ± 13.4 years. One patient with BPA underwent an unsuccessful postoperative trial of externalized DBS due to lack of efficacy despite intraoperative paresthesia. Eleven patients proceeded to full DBS implantation after successful intraoperative and postoperative trials and completed postoperative follow-up duration of 1 year. There were no significant surgical complications in this series and side effects from stimulation were unremarkable. No patients have required electrode or implantable pulse generator revisions to date (as of June 2013). All patients received continuous bipolar DBS with patient control of amplitude up to a clinician-set maximum. Tables 1 and 2 also summarize baseline patient-reported outcome measures for those patients proceeding to full implantation of the DBS system. There were no sta-tistically significant differences in baseline characteristics between pain etiologies. Figure 1 illustrates baseline scores and improvements across the entire 11-patient cohort for all outcome measures. At 1 month after surgery, mean VAS score improved by 60.1% ± 27.3% (p < 0.001), SF-36 improved by 30.1% ± 75.5% (p = 0.553), UWNPS improved by 47.1% ± 37.1% (p < 0.001), and BPI improved by 51.4% ± 33.3% (p < 0.001). Throughout the first year, mean pain relief was sustained, and at 12 months the VAS score was improved from before surgery by 69.6% ± 29.6% (p < 0.001), SF-36 improved by 34.6% ± 69.1% (p = 0.093), UWNPS improved by 50.8% ± 41.2% (p < 0.001), and BPI improved by 57.3% ± 37.8% (p < 0.001).
Results
Although both amputation and BPA subgroups showed significant improvements initially with DBS sustained for 1 year (Table 3 , Figs. 2 and 3) , amputation pain improved the most, with benefits sustained across all pain outcome measures. The BPA pain improvements in overall outcome scores were restricted to the VAS. In the amputation group, after 12 months the mean VAS score improved by 90.0% ± 10.0% (p < 0.001), SF-36 improved by 57.5% ± 97.9% (p = 0.127), UWNPS improved by 80.4% ± 12.7% (p < 0.001), and BPI improved by 79.9% ± 14.7% (p < 0.001). In the BPA group, after 12 months the mean VAS score improved by 52.7% ± 30.2% (p < 0.001), SF-36 improved by 15.6% ± 30.5% (p = 1.000), UWNPS improved by 26.2% ± 40.8% (p = 0.399), and BPI improved by 38.4% ± 41.7% (p = 0.018).
Despite considerable improvements in pain scores, statistically significant overall improvements in SF-36 were not observed, with the exception of amputation pain 1 month after surgery, which improved by 71.4% ± 98.1% (p = 0.013). However, analyses of SF-36 subscores across the entire cohort demonstrated significant and sustained improvements in bodily pain (p < 0.001 throughout) and physical functioning (p = 0.08 at 6 months), with improvements in physical role and general health also approaching statistical significance. In contrast to anecdotal patient reports (Video 1), social functioning, vitality, and emotional and mental health were not significantly improved. Highly significant improvements (p < 0.001) were observed in most UWNPS subscores including sharp, hot, intense, dull, deep, and unpleasant pain, but not cold, sensitive, and itchy pain. Statistical analyses of these subscores by etiological subgroup was not performed to avoid Type I errors, although considerable reductions in hot, sharp, deep, and dull UWNPS subscores in both amputation and BPA pain subgroups suggest DBS relieved both the continuous and paroxysmal components of neuropathic pain. The BPI improvements were statistically 
Discussion
In this report we describe the second-largest recent, open-label, prospective study of DBS for pain, and the largest contemporary single-center experience of DBS for limb injury pain. Although not a new therapy, DBS has advanced considerably over the last two decades, concomitant with advances in both stimulator technology and neuroimaging techniques and, by corollary, improvements in efficacy and reductions in complications. Our results suggest that DBS can consistently deliver analgesia to patients with chronic neuropathic pain after amputation and BPA, with significant sustained improvements at 1 year. These results exceed those predicted by the Oxford experience that it has drawn upon. 5 The authors attribute such success to refined patient selection within specific etiologies suggested to have better outcomes within larger heterogeneous case series. 37, 52, 53 The study also likely benefited from the Oxford neurosurgeons' 15-year learning curve with DBS for pain, thus supporting an argument for only undertaking DBS for pain in centers with access to appropriate expertise and experience, and willing to audit outcomes per EFNS and NICE guidelines. 9 Published peer-reviewed clinical outcomes data in DBS for pain case series comprising at least 6 patients were recently summarized elsewhere. 52, 53 Since the pioneering studies of Mazars et al., Richardson and Akil, and Hosobuchi and Adams, and their long-term followup results published in the 1970s and 1980s, 24, 38, 42, 57 only about 20 groups worldwide have reported long-term efficacy in as many as 83% of patients with follow-up as long as 6 years. Just 5 centers published results in the last decade. 5, 20, 37, 40, 55, 62 Not all authors reported their failed trials that obviated full device implantation, however, leading to overestimation of efficacy in some reports. The literature is obfuscated by varying and simplistic outcome measures that preclude meaningful meta-analysis, such as verbal self-reports comprising only 3 or 5 categories.
Both phantom and stump pain after amputation, and BPA deafferentation pain, qualify as neuropathic pain under its latest definition. 27 We decided to undertake ventroposterolateral rather than periventricular gray DBS, not because of the dogma that thalamic stimulation is more efficacious for nociceptive pain, 3, 37 but drawing upon the Oxford experience of using the ventroposterolateral nucleus of the sensory thalamus as a target with more clearly delineated intraoperative stimulation effects upon the awake or mildly sedated patient, less risk of side effects or morbidity from inaccuracy, and strong somatotopic lo- calization for appendicular pain syndromes. The success of this study leads us to advocate the ventroposterolateral nucleus of the sensory thalamus rather than periventricular gray as the first target of choice for a neurosurgeon commencing DBS for limb pain. One limitation to this investigation that is similar to the late-twentieth century Medtronic trials of DBS for pain is a lack of randomization or case controls. 7 However, other shortcomings of those trials have not affected this study, including a mix of heterogeneous cases, variable deep brain sites stimulated and stimulation parameter cycling, poor enrollment, and loss to follow-up. Nor have problems prevalent in the field of neuromodulation for chronic pain affected this study, including underspecified patient selection criteria and unblinded assessment of patient self-reported outcomes.
Neurosurgical treatments offered for BPA include dorsal root entry zone lesioning, with greatest improve- ments in paroxysmal pain; two-thirds of patients improved long term, yet as many as 10% experience dysesthesia and ipsilateral leg weakness. 1, 13, 58 Motor cortex stimulation (MCS) has also been undertaken with equivocal results influencing paroxysms more than continuous pain, 2, 33 and spinal cord stimulation (SCS) has been reported with limited success. 15, 64 No trials comparing neuromodulation treatments for BPA have been reported. A small comparative case series of 19 amputees has suggested that DBS was superior to SCS and MCS in ameliorating phantom limb pain in 60% of patients versus 32% with SCS and 20% with MCS, with 2 patients with both DBS and MCS implanted experiencing better analgesia from DBS. 30 Mazars et al. reported 5 patients with phantom limb pain whose pain disappeared after thalamic DBS. 42 Other pioneers of DBS for pain such as Hosobuchi, Kumar, Young, and Levy, have all also reported improvements in phantom limb pain with DBS. 23, 31, 38, 63 The Oxford cohort had VAS improvements at 1 year of 38.7% in 7 patients with phantom limb pain and 25.8% in 2 patients with BPA receiving a mixture of thalamic, periventricular gray, and dual-target DBS. 4, 5, 44 Our single-center case series of 12 patients shows greater benefit at 1 year from ventroposterolateral DBS, in particular for amputation pain, suggesting that the therapy retains a role in these difficult-to-treat conditions. Randomized, blinded, controlled clinical trials are desirable, assessing the DBS both on and off, and in revisiting comparisons with other neuromodulatory therapies such as MCS and SCS alongside lesional treatments such as dorsal root entry zone.
An intriguing observation from the results presented here is the considerable and significant improvement in pain scores (VAS, UWNPS, or BPI), without an overall significant improvement in quality of life as measured by the SF-36. While improvements in physical function were noted, negligible improvements in social function, vitality, and emotional and mental health were reported. It is difficult to explain these results without undertaking further qualitative research by interviewing the patients, caregivers, and blinded pain physicians who undertook assessments. However, one can postulate first that pain relief alone in an already functionless limb may have contributed little to altering daily activities for the treated patients and, second, that the patient group who receive this treatment is so debilitated and incapacitated by chronic pain that the more social and emotional domains of their quality of life remain severely impaired despite being considerably improved by relief of pain in an affected limb. Further qualitative, social, and psychological research is desirable to analyze this unexpected finding.
Aside from its established anatomical involvement in pain processing from spinothalamic tracts to the insula, cingulate, and primary somatosensory cortex, the ventral posterior thalamus is implicated in central sensi- tization and descending facilitation of aberrant circuitry in the pain neuromatrix by multiple lines of evidence. 32, 61 Specific mechanisms of central deafferentation and thalamocortical dysrhythmia that implicate sensory thalamic dysfunction in pain are suggested by nonhuman primate lesional and human functional imaging studies, and consequent thalamic reorganization can be large. 26, 28, 39, 50, 54, 60 Microelectrode recordings in patients with chronic pain have shown enhanced bursting activity and increased stump representation in amputees. 10, 11, 35 Patients in pain have characteristically enhanced low-frequency (8-15 Hz) power spectra in ventroposterolateral deep brain macroelectrode local-field potentials.
17 Magnetoencephalography has also implicated disruption of thalamocortical dysrhythmia in the analgesic mechanism of DBS, perhaps by its interrupting low-frequency oscillations and bursting activity. 56 Ventroposterolateral DBS therefore appears to be a more pathophysiologically intuitive treatment than MCS and SCS for phantom limb and BPA deafferentation pain.
Both contemporary and older case series 5, 18 suggest that at least 25% of patients who find success during trial stimulation do not experience long-term success beyond 1 year after surgery. One reason (fortunately avoided here) is loss of patients at follow-up, which makes reaching statistical significance more challenging. Challenges are to identify predictors of long-term efficacy and investigate tolerance. Progressive increases of stimulus amplitude have proven unhelpful. 31 Tolerance may be overcome by subtle alterations of either pulse width, frequency, or both, or failing that, breaks in stimulation. 5 Importantly, the patients in the failed Medtronic trials and many other case series also received episodic cycling DBS, whereas our patients received continuous stimulation. Nevertheless, a subgroup remains either tolerant long term or demonstrates progressive reductions in efficacy. Hypotheses for these results include that patients genuinely become tolerant to the treatment, that a particular pain characteristic is reduced but others unmasked become worse over time, 29 and that chronic pain exhibits disease progression concomitant with increasing severity despite DBS, as has been demonstrated in tremor. 12 Advances in stimulator technology such as the development of demand-driven stimulators may enable patient-controlled analgesia and potentially overcome aspects of tolerance. Long-term follow-up of the patients in this cohort beyond 1 year will be important to adequately assess for tolerance phenomena.
Neuromodulation for neuropathic pain has resulted in positive experiences among physicians, high patient expectations, and positive case series, yet few randomized, controlled, clinical trials. 8, 36 From this promising prospective case-series experience, we encourage continued trials of this therapy for neuropathic pain after limb injury. 
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